Naples
Download the program in PDF format
Friday, May 12
Joint ESMO-AIOM-IQN Path session
Cancer immunotherapy: from basics to clinical practice and sustainability
- Immune checkpoint inhibitors: rational and mechanism of action
J. B.A.G. Haanen (LUMC, NL) - Overview of clinical development of checkpoint inhibitors in solid tumors
J. Bennouna (Nantes, France) - Sustainability of checkpoint inhibitors for the health system
L. G. Mantovani (Università di Milano-Bicocca)
Challenges in the assessment of PD-L1
Harmonization and EQA programs for PD-L1 assessment in Europe. Experience from:
- Germany
P. Schirmacher (QuIP) - France
M.P. Chenard (Strasbourg, AFAQAP) - CIQC
J. Garrat (Vancouver, BC, Canada) - The European Society of Pathology initiative
N.A. ‘t Hart)
- EQA for PD-L1 IHC staining: is it a conundrum?
K. Miller (UK NEQAS)
Liquid biopsy in the clinic: current status and future developments
- The clinical pathway from blood collection to reporting
P. Pauwels (UZA, UA) - Liquid Biopsy in the clinic: currentstatus and future development
M. C. Garassino (Milan) - Results of the joint pilot ctDNA scheme… and next steps
S. Deans (Edinburgh, UK)
New technologies come to the clinic
- Utility of liquid biopsies
S. A. Scudder (Roche) - The GeneReader:A Complete NGS System for Your Lab, Live in 30 Days
S. Cogne (Qiagen) - Advancing Utility of OncoBEAM™ in Clinical Practice
F. S. Jones (Sysmex) - Developments in tools for Oncology testing from Ion Torrent
A. Felton (Thermo Fisher) - Idylla™: easy, rapid and accurate molecular medicine for every patient
P. Valente (Biocartis) - Illumina’s Cancer Research Portfolio and Dedicated Workflows
M. Sohn (Illumina) - QUALITOPIX Image analysis supported assessment of staining sufficiency
A. Schønau (Visiopharm)
Saturday, May 13
Next generation sequencing technologies in the clinic
- EBE-EFPIA PMWG: NGS in Personalized Medicine
C. Dollins (EBE-EFPIA) - French Initiative and NGS extension in molecularpathology
E. Rouleau (Gustave Roussy, Villejuif-France) - The current status of NGS in clinical practice
M. Dietel (Humboldt University, Berlin) - Influence of the reportable range on good performance of NGS methodologies
V. Tack (Ku Leuven, BE)
